Coronaviridae (e.g., Neonatal Calf Diarrhea Virus, Feline Infectious Peritonitis Virus, Canine Coronavirus, Etc.) Patents (Class 424/221.1)
  • Patent number: 10434168
    Abstract: The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: October 8, 2019
    Assignee: Intervet Inc.
    Inventors: Catherine M. Peters, Mark W. Mellencamp, Wenzhi Xue, Terri Wasmoen, Emilio Trigo
  • Patent number: 10130701
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 20, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Patent number: 10010601
    Abstract: The present invention belongs to the field of animal health and provides means to study Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. In a first consideration, the invention relates to a new PRRS virus variant, and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone. Based on this, new PRRS vaccine candidates with improved properties are provided.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 3, 2018
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Andreas Gallei, Christoph Keller, Erik Schacht, Marieke Herrel
  • Patent number: 9017699
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 28, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Publication number: 20150056246
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Patent number: 8846051
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 30, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Publication number: 20140271709
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Brad Eddy, Zhisong QIAO, Kevin O'Connell
  • Publication number: 20140271710
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, in sucrose, arginine, and methionine. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Sandhya BUCHANAN, Kevin O'CONNELL
  • Patent number: 8765142
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: July 1, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Publication number: 20140141041
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Application
    Filed: December 30, 2013
    Publication date: May 22, 2014
    Applicant: VAXIN INC.
    Inventor: De-Chu C. Tang
  • Patent number: 8541003
    Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: September 24, 2013
    Assignee: Protein Sciences Corporation
    Inventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
  • Publication number: 20130224244
    Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.
    Type: Application
    Filed: May 2, 2013
    Publication date: August 29, 2013
    Applicant: THE ROYAL VETERINARY COLLEGE
    Inventor: The Royal Veterinary College
  • Patent number: 8506968
    Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: August 13, 2013
    Assignee: Eli Lilly and Company
    Inventors: Hassibullah Akeefe, Moiz Kitabwalla
  • Patent number: 8470335
    Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: June 25, 2013
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation
    Inventors: Jong Won Oh, Dae Gyun Ahn
  • Patent number: 8444997
    Abstract: The present invention relates to a vaccine composition against feline calicivirus (CFV) infection. The composition comprises a capsid protein of Feline calicivirus-49 (CFV-49), a pharmaceutical accepted carrier and optionally an adjuvant. The present invention further relates to a feline vaccine composition further comprises other live, attenuated or inactivated CVF component in addition to the capsid protein of FCV-49. The present invention also relates to a method for making or using the vaccine compositions.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: May 21, 2013
    Assignee: Zoetis LLC
    Inventors: David E. Lowery, Sing Rong, Paul M. Guimond, Paula M. Clare, Cassius M. Tucker, Thomas Jack Newby
  • Patent number: 8440203
    Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: May 14, 2013
    Assignee: Intervet Inc.
    Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
  • Publication number: 20130045229
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 21, 2013
    Applicant: KINETA, INC.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Patent number: 8313752
    Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: November 20, 2012
    Assignee: Merial Limited
    Inventors: Majid Razzak, Robert Holmes
  • Publication number: 20120269848
    Abstract: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism are also included.
    Type: Application
    Filed: June 18, 2012
    Publication date: October 25, 2012
    Inventors: George A. Scheele, James E. Hildreth
  • Publication number: 20120244182
    Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Nicholas M. VALIANTE
  • Publication number: 20120003277
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Application
    Filed: June 30, 2011
    Publication date: January 5, 2012
    Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James R. Baker, JR., Tarek Hamouda, Susan M. Ciotti
  • Publication number: 20110236419
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 29, 2011
    Inventors: Jean-Christophe Audonnet, Jules Minke
  • Patent number: 8017154
    Abstract: Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: September 13, 2011
    Assignees: Mitsuru Akashi, Masanori Baba
    Inventors: Mitsuru Akashi, Masanori Baba
  • Publication number: 20110212123
    Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 1, 2011
    Inventors: Haixiang Lin, Lie Tao Victor Li
  • Publication number: 20110177116
    Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.
    Type: Application
    Filed: November 6, 2009
    Publication date: July 21, 2011
    Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
  • Patent number: 7981427
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 19, 2011
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Publication number: 20110150929
    Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.
    Type: Application
    Filed: December 28, 2009
    Publication date: June 23, 2011
    Applicant: Eli Lilly and Company
    Inventors: Hassibullah Akeefe, Moiz Kitabwalla
  • Publication number: 20110150940
    Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.
    Type: Application
    Filed: December 16, 2010
    Publication date: June 23, 2011
    Applicant: Universiteit Gent
    Inventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie, Johannes Hubertus Henricus van Eck, Wilhelmus Johannes Mathernus Landman
  • Patent number: 7959927
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: June 14, 2011
    Assignee: Wyeth LLC
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Publication number: 20110135685
    Abstract: The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylactically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.
    Type: Application
    Filed: January 25, 2010
    Publication date: June 9, 2011
    Applicant: SoyMeds, Inc.
    Inventors: Kenneth John Piller, Kenneth Lee Bost
  • Publication number: 20110117129
    Abstract: The present invention is related to methods and attenuated viral compositions for use in preventing and treating a high fever disease forms associated with porcine reproductive and respiratory syndrome (PRRS), such as highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS), a viral disease affecting swine.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 19, 2011
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Michael B. Roof, Eric Vaughn
  • Patent number: 7892563
    Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 22, 2011
    Assignee: Wyeth Holdings Corporation
    Inventor: George R. Siber
  • Publication number: 20100266628
    Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.
    Type: Application
    Filed: April 13, 2010
    Publication date: October 21, 2010
    Inventors: Majid Razzak, Robert Holmes
  • Publication number: 20100266634
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Application
    Filed: February 18, 2010
    Publication date: October 21, 2010
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Publication number: 20100247537
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: September 30, 2010
    Inventors: Cory Ahonen, Randolph Noelle
  • Publication number: 20100233204
    Abstract: The present disclosure relates to multivalent immunogen compositions for treating or preventing diseases or disorders in canines caused by or associated with one or more of canine distemper virus, canine adenovirus (type 1 or type 2), canine parainfluenza virus, canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae, Leptospira grippotyphosa, Leptospira pomona, Leptospira bratislava, Leptospira hardjo, Leptospira autumnalis, Leptospira australis, Leptospira hebdomadis, and Bordetella bronchiseptica. The Leptospira compositions can also be used for treating or preventing leptospirosis diseases or disorders in canine, swine, and bovine.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 16, 2010
    Applicant: WYETH
    Inventor: Michael Alonzo Gill
  • Patent number: 7776340
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 17, 2010
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Patent number: 7767451
    Abstract: The present invention provides a cell strain which is derived from an fcwf-4 cell that is a cell derived from a feline whole fetus and which is capable of being cultured without animal-derived proteins, a method for producing the cell strain, and a method for producing a virus by using the cell. An inexpensive and safe feline vaccine can be produced according to the present invention.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: August 3, 2010
    Assignee: Kyoritsu Seiyaku Corporation
    Inventor: Masami Mochizuki
  • Publication number: 20100172937
    Abstract: Methods for reducing infectivity by providing an enveloped virus neutralizing compound (EVNC) are provided. Methods of preparing a vaccine, vaccine formulations, and methods of immunizing a subject a further provided. Methods of disinfecting a surface are still further provided. In some embodiments, compositions comprising an isolated and purified bioactive EVNC agent are provided.
    Type: Application
    Filed: May 2, 2008
    Publication date: July 8, 2010
    Inventor: Girish J. Kotwal
  • Publication number: 20100158947
    Abstract: The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention.
    Type: Application
    Filed: July 23, 2008
    Publication date: June 24, 2010
    Applicant: GHENT UNIVERSITY
    Inventors: Peter Delputte, Hans Nauwynck, Hanne Van Gorp
  • Patent number: 7740858
    Abstract: Disclosed is SARS-CoV-specific B-cell epitope and applications thereof. The epitopes are peptides and can either be expressed in phages or synthesized to diagnose SARS patients accurately. High sensitivity and specificity of the serologic detection are achievable by using a plurality of SARS-CoV-specific B-cell epitope-based peptides. Therefore, the peptides can be applied to SARS diagnosis and have potentials to be immunogens for producing antibodies against SARS.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: June 22, 2010
    Assignee: National Taiwan University
    Inventors: Han-Chung Wu, I-Ju Liu, Chien-Yu Chiu
  • Patent number: 7722886
    Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: May 25, 2010
    Assignee: Wyeth
    Inventor: George R. Siber
  • Publication number: 20100104599
    Abstract: Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed.
    Type: Application
    Filed: February 22, 2008
    Publication date: April 29, 2010
    Inventors: Ryan Michael Yamka, Kim Gene Friesen, Steven Curtis Zicker
  • Patent number: 7691390
    Abstract: The present invention is directed to an isolated polypeptide containing SEQ ID NO: 1 or an immunogenic fragment thereof. Also disclosed is an isolated nucleic acid encoding the polypeptide or containing a sequence at least 70% identical to SEQ ID NO: 3. Within the scope of this invention are related expression vectors, host cells, and antibodies. Also disclosed are methods of producing the polypeptide, diagnosing coronavirus infection, and identifying a test compound for treating coronavirus infection.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: April 6, 2010
    Inventors: Fang-Jen Lee, Chia-Jung Yu, Ming-Fu Chang, Hong-Nerng Ho
  • Publication number: 20100062019
    Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 11, 2010
    Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
  • Publication number: 20100047277
    Abstract: Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one viral surface envelope glycoprotein expressed on the surface of the virosome. The virosome can also optionally include at least one adjuvant molecule expressed on the surface of the virosome.
    Type: Application
    Filed: July 12, 2007
    Publication date: February 25, 2010
    Inventors: Richard W. Compans, Chinglai Yang, Qizhi Yao, Sang-moo Kang
  • Publication number: 20100040576
    Abstract: The invention relates to compositions and methods related to the treatment of viral infection. In some embodiments, the invention relates to the treatment of hepatitis C viral infection. In further embodiments, the invention relates to methods of administering oligonucleotide compositions for treating viral infections. In still further embodiments, the invention relates to the administration of antiviral agents, corticosteroids and immunomodulatory agents. In additional embodiments, the invention relates to the manipulation of immunostimulatory motifs within the oligonucleotides.
    Type: Application
    Filed: December 16, 2008
    Publication date: February 18, 2010
    Inventors: Chia-Cheng Kao, Kumar Ranjith Tharachaparamba
  • Publication number: 20100028383
    Abstract: The present invention relates to a stabiliser composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabiliser composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabiliser composition with a biological molecule and/or a micro-organism; to the use of such a stabiliser composition, and of vaccines prepared therewith.
    Type: Application
    Filed: March 7, 2006
    Publication date: February 4, 2010
    Applicant: INTERVET INTERNATIONAL B.V.
    Inventors: Petrus Theodorus Johannes Andries van Gelder, Arnoldus Theodorus Petrus Loermans, Mathias Arnold Maassen
  • Publication number: 20100028379
    Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
    Type: Application
    Filed: November 23, 2007
    Publication date: February 4, 2010
    Applicants: PFIZER, INC, PFIZER PRODUCTS INC.
    Inventors: Cassius M. Tucker, John David Haworth